US 2017/0320912 A1 · PEPTIDES

Abstract

The present invention relates to dual-site BACE1 inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

Claims18

Dependent claims

A dual-site BACE1 inhibitor, binding to both, the enzymatic active site and the catalytic domain of the BACE enzyme.

Dependencies are inferred from the claim text.

Facts

Application

15/528,204Filed 25 Nov 2015

Priority

EP 14195325.728 Nov 2014

Published

9 Nov 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

C07K 7/08
Linear peptides containing only normal peptide links: having 12 to 20 amino acids
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00

Abstract

Claims18

Dependent claims

A dual-site BACE1 inhibitor, binding to both, the enzymatic active site and the catalytic domain of the BACE enzyme.

Dependencies are inferred from the claim text.

Peptides

Life of this patent

Abstract

Claims18

Peptides

Life of this patent

Abstract

Claims18